Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer. J Thorac Oncol. 2020 May 7. pii: S1556-0864(20)30373-7. doi: 10.1016/j.jtho.2020.04.026. [Epub ahead of prin…

Assessment of Immune-Related Interstitial Lung Disease in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Multi-Center Prospective Study. J Thorac Oncol. 2020 Apr 11. pii: S1556-0864(20)30297-5. doi: 10.101…